eFFECTOR Therapeutics, Inc.
11180 Roselle Street
About eFFECTOR Therapeutics, Inc.
20 articles with eFFECTOR Therapeutics, Inc.
eFFECTOR’s Tomivosertib Demonstrates Positive Phase 2 Results for Subjects with Non-Small Cell Lung Cancer in Combination with Checkpoint Inhibitors
eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors for the treatment of cancer, announced that positive Phase 2 data from its pipeline program tomivosertib, will be presented at the ASCO 2020 Virtual Scientific Program at 8:00 a.m. ET on May 29.
eFFECTOR’s Zotatifin Demonstrates in vitro Anti-SARS-CoV-2 Activity in Independent International Study Reported in Peer-Reviewed Journal Nature
eFFECTOR Therapeutics, Inc., announced that preliminary results from an independent preclinical study showed that oncology product candidate zotatifin had in vitro antiviral activity against SARS-CoV-2, the virus that causes COVID-19.
eFFECTOR’s Zotatifin (eFT226) Inhibited Tumor Growth and Caused Tumor Regression Across Diverse Receptor Tyrosine Kinase-Driven Tumor Types in Preclinical Models of Disease
Study Presented in Virtual Session at AACR Annual Meeting Provides Evidence of Potential for Zotatifin to Drug an Important Class of Oncogene Drivers
eFFECTOR Therapeutics, Inc. announced that Steve Worland, Ph.D., president and chief executive officer of eFFECTOR, will present a company overview during the BIO CEO & Investor Conference on Tuesday, February 11 at 2:00 p.m. ET.
Pfizer and Effector Therapeutics inked a global license and collaboration deal to develop small-molecule inhibitors of eukaryotic initiation factor 4E, also known as eIF4E.
eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-in-Class Inhibitors of eIF4E to Treat Multiple Cancer Types
eFFECTOR Therapeutics, Inc. and Pfizer Inc. announced an exclusive worldwide license and collaboration agreement to develop small-molecule inhibitors of eukaryotic initiation factor 4E, a key oncogenic driver located downstream from both the RAS and PI3K signaling pathways.
eFFECTOR Therapeutics Initiates Phase 1/2 Safety and Efficacy Study of Zotatifin (eFT226) in Patients with Advanced Solid Tumor Malignancies
Program addresses aggressive cancers with RTK (HER2, ERBB3, FGFR1, FGFR2) and KRAS mutations
eFFECTOR Therapeutics Announces Clinical Collaboration with Merck to Conduct a Phase 2 Combination Trial to Evaluate eFFECTOR's Tomivosertib (eFT508) with KEYTRUDA® (pembrolizumab) for Metastatic Triple Negative Breast Cancer
eFFECTOR Therapeutics, Inc. today announced it has entered into a clinical collaboration agreement with Merck (known as MSD outside the United States and Canada), through a subsidiary, to evaluate the combination of eFFECTOR's tomivosertib (eFT508), an oral, small molecule inhibitor of MNK1/2, with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), for the treatment of patients with metastatic triple negative breast cancer (TNBC).
eFFECTOR Initiates Dosing In Phase II Combination Trial Of Eft508 And Avelumab In Microsatellite Stable Colorectal Cancer
eFFECTOR To Collaborate With Pfizer And Merck KGaA, Darmstadt, Germany To Evaluate A Novel Immuno-Oncology Combination In Microsatellite Stable Colorectal Cancer
Cancer Genetics Is Selected By eFFECTOR To Provide Biomarker Discovery And Development Services For Novel Oncology Drugs
eFFECTOR' Lead Product Candidate, Eft508, Receives Orphan Designation From FDA For Treatment Of Diffuse Large B-Cell Lymphoma